{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:47:13Z","timestamp":1791521233739,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":3334,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.bbadis.2004.02.005","type":"journal-article","created":{"date-parts":[[2004,3,16]],"date-time":"2004-03-16T10:24:03Z","timestamp":1079432643000},"page":"103-113","source":"Crossref","is-referenced-by-count":105,"title":["Causative factors behind poloxamer 188 (Pluronic F68, Flocor\u2122)-induced complement activation in human sera"],"prefix":"10.1016","volume":"1689","author":[{"given":"S.Moein","family":"Moghimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.Christy","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Dadswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandor","family":"Savay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl R","family":"Alving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janos","family":"Szebeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2004.02.005_BIB1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0167-7799(00)01485-2","article-title":"Poloxamers and poloxamines in nanoparticle engineering and experimental medicine","volume":"18","author":"Moghimi","year":"2000","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jnci\/88.11.766","article-title":"Poloxamer-188 revisited: a potentially valuable immune modulator?","volume":"88","author":"Moghimi","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V90.5.2041","article-title":"RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study","volume":"90","author":"Adams-Graves","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB4","first-page":"117","article-title":"The effect of RheothRx injection on the hemorheological parameters in patients with acute myocardial infarction-(CORE trial sub-study)","volume":"17","author":"Toth","year":"1997","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-8703(98)70037-7","article-title":"Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction","volume":"135","author":"Maynard","year":"1998","journal-title":"Am. Heart J."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB6","first-page":"3262","article-title":"Phase I study of FLOCOR in patients with acute chest syndrome of sickle cell disease","volume":"94","author":"Luchtman-Jones","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB7","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.286.17.2099","article-title":"Purified poloxamer 188 for the treatment of acute vaso-occlusive crisis of sickle cell disease: a double-blind, randomized, placebo-controlled study","volume":"286","author":"Orringer","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB8","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/jps.10190","article-title":"Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans","volume":"91","author":"Grindel","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V59.6.1299.1299","article-title":"Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis","volume":"59","author":"Vercellotti","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00005344-199309000-00017","article-title":"Activation of complement by Fluosol attributes to the Pluronic detergent micelle structure","volume":"22","author":"Ingram","year":"1993","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB11","first-page":"428","article-title":"The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA","volume":"12","author":"Tremper","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00003246-198502000-00008","article-title":"Pulmonary complications after Fluosol administration to patients with life-threatening blood loss","volume":"13","author":"Police","year":"1985","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB13","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/0360-3016(89)90967-X","article-title":"Phase I\/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumours of the head and neck","volume":"16","author":"Lustig","year":"1989","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0002-9149(90)90836-P","article-title":"Reduction of myocardial ischemia during percutaneous coronary angioplasty with oxygenated Fluosol","volume":"66","author":"Kent","year":"1990","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1046\/j.1537-2995.1991.31791368343.x","article-title":"Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies","volume":"31","author":"Hong","year":"1991","journal-title":"Transfusion"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF02802311","article-title":"Anaphylactoid reactions to radiocontrast material","volume":"9","author":"Liberman","year":"1991","journal-title":"Clin. Rev. Allergy"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.50","article-title":"Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents","volume":"18","author":"Szebeni","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/90.4.300","article-title":"Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study","volume":"90","author":"Szebeni","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1567-5769(01)00006-6","article-title":"Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions","volume":"1","author":"Szebeni","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB20","first-page":"283","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1359-6446(02)02444-3","article-title":"Therapeutic synthetic polymers: a game of Russian roulette?","volume":"7","author":"Hunter","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u2032(2)-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0378-5173(82)90033-3","article-title":"Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow","volume":"82","author":"Porter","year":"1992","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB24","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1021\/ma00111a026","article-title":"Micelle formation and solubilization of fluorescent probes in poly(oxyethylene-b-oxypropylene-b-oxyethylene) solutions","volume":"28","author":"Kabanov","year":"1995","journal-title":"Macromolecules"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0925-4439(93)90056-7","article-title":"The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4","volume":"1180","author":"Gibb","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB26","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.CIR.99.17.2302","article-title":"Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs. A model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and inhibition by soluble CR1 and anti-C5a antibody","volume":"99","author":"Szebeni","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1537-2995.1988.28488265271.x","article-title":"Reduction in toxicity of a component of an artificial blood substitute by supercritical fluid fractionation","volume":"28","author":"Lane","year":"1988","journal-title":"Transfusion"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB28","unstructured":"R.M. Emanuele, R.L. Hunter, P.H. Culbreth, Polyoxypropylene\/polyoxyethylene copolymers with improved biological activity. US Patent (1999) 5,990,241."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02894385","article-title":"A review of block copolymer surfactants","volume":"54","author":"Schmolka","year":"1976","journal-title":"J. Am. Oil Chem. Soc."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0141-3910(02)00079-4","article-title":"Thermal oxidation of poly(ethylene oxide-propylene oxide-ethylene oxide) triblock copolymer: focus on low molecular weight degradation products","volume":"77","author":"Gallet","year":"2002","journal-title":"Polym. Degrad. Stab."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10731199909117691","article-title":"Evaluation of commercial and purified Pluronic\u00ae F-68 in a human blood neutrophil bioassay","volume":"27","author":"Edwards","year":"1999","journal-title":"Artif. Cells Blood Substit. Immobil. Biotechnol."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB32","doi-asserted-by":"crossref","first-page":"167S","DOI":"10.1042\/bst023167s","article-title":"Activation of complement by DMSO and ethanol and its inhibition by soluble complement receptor type 1","volume":"23","author":"Laver","year":"1995","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB33","first-page":"207","article-title":"Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal","volume":"7","author":"Kessel","year":"1995","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/1357-2725(95)00030-S","article-title":"Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteins","volume":"27","author":"Woodburn","year":"1995","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB35","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/elps.11501401214","article-title":"Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis","volume":"14","author":"Blunk","year":"1993","journal-title":"Electrophoresis"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.30","article-title":"Capture of stealth nanoparticles by body's defences","volume":"18","author":"Moghimi","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.bbadis.2004.02.005_BIB37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0162-3109(87)90031-2","article-title":"Effects of anaphylatoxins on circulation","volume":"14","author":"Marceau","year":"1987","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.bbadis.2004.02.005_BIB38","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/ki.1994.468","article-title":"Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro","volume":"46","author":"Cheung","year":"1994","journal-title":"Kidney Int."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443904000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443904000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T03:53:09Z","timestamp":1682653989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443904000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0925443904000262"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2004.02.005","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}